28 related articles for article (PubMed ID: 26763361)
1. Reply to “Response to “CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110-1114.
Paíno T; Paiva B; San Miguel J
Haematologica; 2013 Jan; 98(1):e10. PubMed ID: 23397607
[No Abstract] [Full Text] [Related]
2. One missense mutation in exon 2 of the PAX5 gene in Iran.
Yazdanparast S; Khatami SR; Galehdari H; Jaseb K
Genet Mol Res; 2015 Dec; 14(4):17768-75. PubMed ID: 26782422
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response.
Fukumoto K; Fujisawa M; Suehara Y; Narita KT; Usui Y; Takeuchi M; Matsue K
Leuk Lymphoma; 2016 Aug; 57(8):1786-92. PubMed ID: 26764045
[TBL] [Abstract][Full Text] [Related]
4. CD138-negative plasma cell myeloma: a diagnostic challenge and a unique entity.
Setiadi AF; Sheikine Y
BMJ Case Rep; 2019 Dec; 12(11):. PubMed ID: 31791993
[TBL] [Abstract][Full Text] [Related]
5. PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).
Sato K; Sakai H; Kato M; Nishio Y; Tsuruoka Y; Uemura Y; Yokoi S; Saito T; Matsunawa M; Suzuki Y; Isobe Y; Inoue Y; Takahashi M; Miura I
Int J Hematol; 2015 Jun; 101(6):608-11. PubMed ID: 25633778
[TBL] [Abstract][Full Text] [Related]
6. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
An G; Xu Y; Shi L; Zou D; Deng S; Sui W; Xie Z; Hao M; Chang H; Qiu L
Leuk Res; 2013 Oct; 37(10):1251-7. PubMed ID: 23927993
[TBL] [Abstract][Full Text] [Related]
7. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.
Hoyer JD; Hanson CA; Fonseca R; Greipp PR; Dewald GW; Kurtin PJ
Am J Clin Pathol; 2000 Jun; 113(6):831-7. PubMed ID: 10874884
[TBL] [Abstract][Full Text] [Related]
8. Diffuse large B-cell lymphoma carrying t(9;14)(p13;q32)/PAX5-immunoglobulin heavy chain gene is characterized by nuclear positivity of MUM1 and PAX5 by immunohistochemistry.
Ohno H; Nakagawa M; Kishimori C; Fukutsuka K; Maekawa F; Takeoka K; Hayashida M; Sakamoto S; Akasaka T; Honjo G
Hematol Oncol; 2020 Apr; 38(2):171-180. PubMed ID: 31955451
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32).
Kobayashi H; Saito H; Kitano K; Kiyosawa K; Gaun S; Aoki K; Narita A; Watanabe M; Uchimaru K; Motokura T
Acta Haematol; 1995; 94(4):199-203. PubMed ID: 8610478
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5.
Yokoi S; Sakai H; Uchida A; Uemura Y; Sato K; Tsuruoka Y; Nishio Y; Matsunawa M; Suzuki Y; Isobe Y; Kato M; Inoue Y; Hoshikawa M; Miura I
J Clin Exp Hematop; 2015; 55(3):137-43. PubMed ID: 26763361
[TBL] [Abstract][Full Text] [Related]
11. The t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.
Ohno H; Ueda C; Akasaka T
Leuk Lymphoma; 2000 Feb; 36(5-6):435-45. PubMed ID: 10784387
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
Paner A; Patel P; Dhakal B
Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]